{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:18:39Z","timestamp":1789953519785,"version":"4.0.1"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.2515\/therapie\/2013068","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T14:00:10Z","timestamp":1402668010000},"page":"115-128","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacologie du ph\u00e9nom\u00e8ne de Raynaud"],"prefix":"10.1016","volume":"69","author":[{"given":"Matthieu","family":"Roustit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Villier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Carpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.2515\/therapie\/2013068_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.2515\/therapie\/2013068_bb0010","series-title":"De l\u2019asphyxie locale et de la gangr\u00e8ne symm\u00e9trique des extr\u00e9mit\u00e9s","author":"Raynaud","year":"1862"},{"key":"10.2515\/therapie\/2013068_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e289","article-title":"Diagnosis and management of Raynaud\u2019s phenomenon","volume":"344","author":"Goundry","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0020","first-page":"70","article-title":"Geographic variation in the prevalence of Raynaud\u2019s phenomenon: Charleston, SC, USA, vs. Tarentaise, Savoie, France","volume":"20","author":"Maricq","year":"1993","journal-title":"J Rheumatol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0025","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jvs.2006.07.037","article-title":"Incidence and natural history of Raynaud phenomenon: a long-term follow-up (14 years) of a random sample from the general population","volume":"44","author":"Carpentier","year":"2006","journal-title":"J Vasc Surg"},{"issue":"Suppl 3","key":"10.2515\/therapie\/2013068_bb0030","first-page":"iii19","article-title":"Digital ulcers: overt vascular disease in systemic sclerosis","volume":"48","author":"Steen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0035","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","article-title":"Mechanisms of Raynaud\u2019s disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vascular medicine (London, England)"},{"key":"10.2515\/therapie\/2013068_bb0040","first-page":"7","article-title":"Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation of the fingers, a variety of Raynaud\u2019s disease","volume":"15","author":"Lewis","year":"1929","journal-title":"Heart"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0045","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/01.CIR.80.4.859","article-title":"Induction of vasospastic attacks despite digital nerve block in Raynaud\u2019s disease and phenomenon","volume":"80","author":"Freedman","year":"1989","journal-title":"Circulation"},{"issue":"Suppl 10","key":"10.2515\/therapie\/2013068_bb0050","doi-asserted-by":"crossref","first-page":"121s","DOI":"10.1042\/cs068s121","article-title":"Modulation of postjunctional alpha-adrenergic responsiveness by local changes in temperature","volume":"68","author":"Vanhoutte","year":"1985","journal-title":"Clin Sci"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0055","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","article-title":"Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation","volume":"94","author":"Bailey","year":"2004","journal-title":"Circ Res"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0060","doi-asserted-by":"crossref","first-page":"H1700","DOI":"10.1152\/ajpheart.01078.2006","article-title":"Cold-induced cutaneous vasoconstriction is mediated by Rho kinase in vivo in human skin","volume":"292","author":"Thompson-Torgerson","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0065","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1152\/japplphysiol.00407.2010","article-title":"Local thermal control of the human cutaneous circulation","volume":"109","author":"Johnson","year":"2010","journal-title":"J Appl Physiol"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0070","doi-asserted-by":"crossref","first-page":"H324","DOI":"10.1152\/ajpheart.00246.2011","article-title":"Impaired transient vasodilation and increased vasoconstriction to digital local cooling in primary Raynaud\u2019s phenomenon","volume":"301","author":"Roustit","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0075","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/art.20214","article-title":"Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud\u2019s disease","volume":"50","author":"Furspan","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0080","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.92.6.1448","article-title":"Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1-adrenergic antagonists in idiopathic Raynaud\u2019s disease","volume":"92","author":"Freedman","year":"1995","journal-title":"Circulation"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rdc.2007.12.005","article-title":"Regulation of vascular reactivity in scleroderma: new insights into Raynaud\u2019s phenomenon","volume":"34","author":"Flavahan","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"8730","key":"10.2515\/therapie\/2013068_bb0090","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","article-title":"Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon","volume":"336","author":"Bunker","year":"1990","journal-title":"Lancet"},{"issue":"8863","key":"10.2515\/therapie\/2013068_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","article-title":"Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud\u2019s phenomenon","volume":"342","author":"Bunker","year":"1993","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.2515\/therapie\/2013068_bb0100","doi-asserted-by":"crossref","first-page":"v14","DOI":"10.1093\/rheumatology\/ken279","article-title":"The microvascular endothelium in scleroderma","volume":"47","author":"Kahaleh","year":"2008","journal-title":"Rheumatology Oxford"},{"issue":"19","key":"10.2515\/therapie\/2013068_bb0105","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.2515\/therapie\/2013068_bb0110","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrrheum.2010.102","article-title":"Cellular and molecular aspects of vascular dysfunction in systemic sclerosis","volume":"6","author":"Trojanowska","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0889-857X(21)01041-3","article-title":"Microvasculature in systemic sclerosis","volume":"16","author":"Carpentier","year":"1990","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jmv.2012.05.005","article-title":"Bilan \u00e9tiologique minimal du ph\u00e9nom\u00e8ne de Raynaud : un consensus d\u2019experts","volume":"37","author":"Pistorius","year":"2012","journal-title":"J Mal Vasc"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0125","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3899\/jrheum.081030","article-title":"Raynaud\u2019s phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis","volume":"36","author":"Sulli","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0130","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/cs0960577","article-title":"Cardiovascular responses evoked by mild cool stimuli in primary Raynaud\u2019s disease: the role of endothelin","volume":"96","author":"Edwards","year":"1999","journal-title":"Clin Sci"},{"issue":"8724","key":"10.2515\/therapie\/2013068_bb0135","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","article-title":"Serum endothelin-1 concentrations and cold provocation in primary Raynaud\u2019s phenomenon","volume":"336","author":"Zamora","year":"1990","journal-title":"Lancet"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0140","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3899\/jrheum.080924","article-title":"Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis","volume":"36","author":"Blaise","year":"2009","journal-title":"J Rheumatol"},{"key":"10.2515\/therapie\/2013068_bb0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/rheumatology\/41.8.843","article-title":"Beauty and the beast. The nitric oxide paradox in systemic sclerosis","volume":"41","author":"Matucci Cerinic","year":"2002","journal-title":"Rheumatology Oxford"},{"issue":"20","key":"10.2515\/therapie\/2013068_bb0150","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0155","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR scleroderma trials and research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology Oxford"},{"issue":"8","key":"10.2515\/therapie\/2013068_bb0165","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0170","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jvs.2013.03.012","article-title":"Current medical and surgical management of Raynaud\u2019s syndrome","volume":"57","author":"Landry","year":"2013","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0175","first-page":"858","article-title":"Inefficacy of diltiazem in the treatment of Raynaud\u2019s phenomenon with associated connective tissue disease: a double blind placebo controlled study","volume":"14","author":"Da Costa","year":"1987","journal-title":"J Rheumatol"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0180","first-page":"724","article-title":"A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud\u2019s phenomenon","volume":"12","author":"Rhedda","year":"1985","journal-title":"J Rheumatol"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI12020","article-title":"Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients","volume":"108","author":"Stratton","year":"2001","journal-title":"J Clin Invest"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0190","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1136\/annrheumdis-2012-201400","article-title":"Prostaglandin I2 analogues enhance already exuberant Th17 cell responses in systemic sclerosis","volume":"71","author":"Truchetet","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.2515\/therapie\/2013068_bb0195","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"1998","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0205","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I","article-title":"Oral iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study","volume":"41","author":"Wigley","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.2515\/therapie\/2013068_bb0210","article-title":"Oral vasodilators for primary Raynaud\u2019s phenomenon","volume":"7","author":"Stewart","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0215","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jaad.2006.02.004","article-title":"A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis","volume":"54","author":"Chung","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0220","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar4216","article-title":"Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion","volume":"15","author":"Shah","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0225","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0235","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0240","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/rheumatology\/kep413","article-title":"Effect of the dual endothelin receptor antagonist bosentan on Raynaud\u2019s phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study","volume":"49","author":"Nguyen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0245","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10067-009-1157-4","article-title":"No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis","volume":"28","author":"Hettema","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3899\/jrheum.120416","article-title":"Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by Nailfold capillaroscopic analysis in systemic sclerosis","volume":"40","author":"Cutolo","year":"2013","journal-title":"J Rheumatol"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0255","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/ket019","article-title":"Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study","volume":"52","author":"Parisi","year":"2013","journal-title":"Rheumatology"},{"key":"10.2515\/therapie\/2013068_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000956","article-title":"Prazosin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","author":"Harding","year":"1998","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0265","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/clpt.1986.166","article-title":"Double-blind, placebo-controlled study of prazosin in Raynaud\u2019s phenomenon","volume":"40","author":"Wollersheim","year":"1986","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0270","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0950-821X(89)80066-0","article-title":"The efficacy of thymoxamine in primary Raynaud\u2019s phenomenon","volume":"3","author":"Grigg","year":"1989","journal-title":"Eur J Vasc Surg"},{"issue":"6155","key":"10.2515\/therapie\/2013068_bb0275","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.1.6155.20-a","article-title":"Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud\u2019s phenomenon","volume":"1","author":"Nilsen","year":"1979","journal-title":"Br Med J"},{"issue":"Pt 3","key":"10.2515\/therapie\/2013068_bb0280","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1113\/jphysiol.2006.109884","article-title":"The involvement of nitric oxide in the cutaneous vasoconstrictor response to local cooling in humans","volume":"574","author":"Hodges","year":"2006","journal-title":"J Physiol"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0285","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.01305.2004","article-title":"Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries","volume":"289","author":"Bailey","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"19","key":"10.2515\/therapie\/2013068_bb0290","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0295","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"J Rheumatol"},{"issue":"Suppl 10","key":"10.2515\/therapie\/2013068_bb0300","first-page":"2086","article-title":"Efficacy of Tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis: adouble-blind randomized placebo-controlled parallel group multicentric study [Abstract]","volume":"62","author":"Agarwal","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0305","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0310","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud\u2019s phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.2515\/therapie\/2013068_bb0315","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: arandomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0320","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud\u2019s phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0325","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud\u2019s condition score in patients with Raynaud\u2019s phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0330","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/clpt.2011.302","article-title":"Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud\u2019s phenomenon","volume":"91","author":"Roustit","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0335","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/rheumatology\/35.12.1281","article-title":"Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud\u2019s phenomenon and systemic sclerosis","volume":"35","author":"Anderson","year":"1996","journal-title":"Br J Rheumatol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0340","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/01.CIR.3.5.681","article-title":"The effect of local application of glyceryl trinitrate (nitroglycerine) on Raynaud\u2019s disease and Raynaud\u2019s phenomenon studies on blood flow and clinical manifestations","volume":"3","author":"Kleckner","year":"1951","journal-title":"Circulation"},{"issue":"8263","key":"10.2515\/therapie\/2013068_bb0345","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","article-title":"Topical glyceryl trinitrate as adjunctive treatment in Raynaud\u2019s disease","volume":"1","author":"Franks","year":"1982","journal-title":"Lancet"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0350","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0355","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1124\/jpet.113.205484","article-title":"Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats","volume":"346","author":"Kotzki","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.2515\/therapie\/2013068_bb0360","first-page":"S636","article-title":"A double-blind placebo-controlled crossover trial of the alpha-2c adrenoceptor antagonist orm-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis [Abstract]","volume":"64","author":"Herrick","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0365","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/acr.21622","article-title":"Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud\u2019s phenomenon","volume":"64","author":"Fava","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0370","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mvr.2005.12.002","article-title":"Exaggerated local hand sympathetic but not renin\u2013angiotensin system activation in patients with primary Raynaud\u2019s phenomenon","volume":"71","author":"Coppo","year":"2006","journal-title":"Microvasc Res"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0375","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1997.00219.x","article-title":"The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud\u2019s phenomenon","volume":"242","author":"Pancera","year":"1997","journal-title":"J Intern Med"},{"issue":"11","key":"10.2515\/therapie\/2013068_bb0380","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud\u2019s phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0385","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud\u2019s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0390","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1160\/TH12-05-0337","article-title":"Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation","volume":"108","author":"Antonopoulos","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0395","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1196\/annals.1423.070","article-title":"Statins as immunomodulators in systemic sclerosis","volume":"1110","author":"Abou-Raya","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0400","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/art.21899","article-title":"Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis","volume":"54","author":"Kuwana","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.2515\/therapie\/2013068_bb0405","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjcard.2008.10.008","article-title":"Comparison of effects of rosuvastatin (10 mg) versusatorvastatin (40 mg) on Rho kinase (ROCK) activity in men with a previous atherosclerotic event","volume":"103","author":"Rawlings","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie\/2013068_bb0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/000331976001100301","article-title":"Raynaud\u2019s disease, Raynaud\u2019s phenomenon, and serotonin","volume":"11","author":"Halpern","year":"1960","journal-title":"Angiology"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/000331979304400213","article-title":"Case of fluoxetine-induced remission of Raynaud\u2019s phenomenon-a case report","volume":"44","author":"Bolte","year":"1993","journal-title":"Angiology"},{"issue":"8961","key":"10.2515\/therapie\/2013068_bb0425","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(95)92582-1","article-title":"Serotonin reuptake inhibitors in Raynaud\u2019s phenomenon","volume":"345","author":"Jaffe","year":"1995","journal-title":"Lancet"},{"issue":"9","key":"10.2515\/therapie\/2013068_bb0430","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud\u2019s phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0435","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0006-3223(97)00188-1","article-title":"Fluoxetine-induced Raynaud\u2019s phenomenon","volume":"41","author":"Rudnick","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"9","key":"10.2515\/therapie\/2013068_bb0440","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/000331979604700909","article-title":"Digital infarction in a patient with Raynaud\u2019s phenomenon associated with treatment with a specific serotonin reuptake inhibitor. A case report","volume":"47","author":"Bell","year":"1996","journal-title":"Angiology"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0445","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00296-006-0254-9","article-title":"Citalopram-induced Raynaud\u2019s phenomenon","volume":"27","author":"Peir\u00f3","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.2515\/therapie\/2013068_bb0450","article-title":"Ketanserin for Raynaud\u2019s phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"1998","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0455","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nrrheum.2011.203","article-title":"SSc in 2011: from mechanisms to medicines","volume":"8","author":"Mouthon","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0460","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/rheumatology\/kep039","article-title":"The efficacy of complementary and alternative medicine in the treatment of Raynaud\u2019s phenomenon: a literature review and meta-analysis","volume":"48","author":"Malenfant","year":"2009","journal-title":"Rheumatology"},{"key":"10.2515\/therapie\/2013068_bb0465","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/580704","article-title":"Results of a pilot randomized placebo-controlled trial in primary and secondary Raynaud\u2019s phenomenon with St. John\u2019s wort: detecting changes in angiogenic cytokines when rp improves","author":"Malenfant","year":"2011","journal-title":"Isrn Rheumatol"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0470","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1358863X9700200404","article-title":"The occurrence of Raynaud\u2019s phenomenon in a general population: the Framingham Study","volume":"2","author":"Brand","year":"1997","journal-title":"Vasc Med Lond Engl"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0475","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/0003319711432861","article-title":"The association of Raynaud syndrome with \u03b2-blockers: a meta-analysis","volume":"63","author":"Mohokum","year":"2012","journal-title":"Angiology"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0480","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0954-6820.1983.tb03755.x","article-title":"Complaints of cold extremities among patients on antihypertensive treatment","volume":"213","author":"Feleke","year":"1983","journal-title":"Acta Med Scand"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0485","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/01.CIR.72.3.466","article-title":"Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud\u2019s phenomenon","volume":"72","author":"Coffman","year":"1985","journal-title":"Circulation"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0490","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/j.1552-4604.1992.tb05777.x","article-title":"The influence of different beta-blocking drugs on the peripheral circulation in Raynaud\u2019s phenomenon and in hypertension","volume":"32","author":"Franssen","year":"1992","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0495","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0026-2862(87)90023-9","article-title":"\u03b2-blockers: a new therapeutic approach to Raynaud\u2019s disease","volume":"33","author":"Brotzu","year":"1987","journal-title":"Microvasc Res"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0500","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-2125.1982.tb02045.x","article-title":"Effect of beta-adrenoceptor antagonists on prevalence of peripheral vascular symptoms in hypertensive patients","volume":"14","author":"Steiner","year":"1982","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0505","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/art.1780360517","article-title":"Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud\u2019s disease","volume":"36","author":"Freedman","year":"1993","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0510","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.1984.00350160096017","article-title":"Prevalence of raynaud\u2019s phenomenon in patients with migraine","volume":"144","author":"Zahavi","year":"1984","journal-title":"Arch Intern Med"},{"issue":"pt1","key":"10.2515\/therapie\/2013068_bb0515","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/123.1.9","article-title":"Ergotamine in the acute treatment of migraine: a review and European consensus","volume":"123","author":"Tfelt-Hansen","year":"2000","journal-title":"Brain"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0520","first-page":"245","article-title":"Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature","volume":"43","author":"Safar","year":"2002","journal-title":"J Cardiovasc Surg (Torino)"},{"issue":"7978","key":"10.2515\/therapie\/2013068_bb0525","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(76)92381-3","article-title":"Digital vasospasm with bromocriptine","volume":"2","author":"Duvoisin","year":"1976","journal-title":"Lancet"},{"issue":"11","key":"10.2515\/therapie\/2013068_bb0530","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/0248-8663(96)88128-8","article-title":"Ph\u00e9nom\u00e8ne de Raynaud avec microangiopathie organique et traitement prolong\u00e9 par bromocriptine","volume":"17","author":"Zenone","year":"1996","journal-title":"Rev Med Interne"},{"issue":"13-14","key":"10.2515\/therapie\/2013068_bb0535","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/0959-8049(95)00460-2","article-title":"Secondary Raynaud\u2019s phenomenon and other late vascular complications following chemotherapy for testicular cancer","volume":"31A","author":"Berger","year":"1995","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0540","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1002\/cncr.24981","article-title":"Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer","volume":"116","author":"Glendenning","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0545","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2012.43.2872","article-title":"Bleomycin-induced Raynaud\u2019s phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion","volume":"31","author":"McGrath","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0550","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2340\/0001555572465","article-title":"Raynaud\u2019s phenomenon and intralesional bleomycin","volume":"72","author":"De Pablo","year":"1992","journal-title":"Acta Derm Venereol"},{"issue":"5 Pt 1","key":"10.2515\/therapie\/2013068_bb0555","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0190-9622(08)80370-2","article-title":"Intralesional bleomycin and Raynaud\u2019s phenomenon","volume":"24","author":"Epstein","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"10.2515\/therapie\/2013068_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0190-9622(08)80323-4","article-title":"Intralesional bleomycin and Raynaud\u2019s phenomenon","volume":"26","author":"Gregg","year":"1992","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0565","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1525-1470.2001.018003249.x","article-title":"Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin","volume":"18","author":"Vanhooteghem","year":"2001","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0570","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0190-9622(85)80353-4","article-title":"Persisting Raynaud\u2019s phenomenon following intralesional bleomycin treatment of finger warts","volume":"13","author":"Epstein","year":"1985","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0575","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejim.2012.03.016","article-title":"The association of Raynaud\u2019s syndrome with cisplatin-based chemotherapy - a meta-analysis","volume":"23","author":"Mohokum","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.2515\/therapie\/2013068_bb0580","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/BOR.0b013e32834b1606","article-title":"New insights on chemically induced animal models of systemic sclerosis","volume":"23","author":"Batteux","year":"2011","journal-title":"Current opinion in rheumatology"},{"issue":"12","key":"10.2515\/therapie\/2013068_bb0585","first-page":"1983","article-title":"5-Fluorouracil-induced Raynaud\u2019s phenomenon","volume":"34","author":"Papamichael","year":"1998","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0590","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/s10165-011-0472-1","article-title":"Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases","volume":"22","author":"Tamaki","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0595","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.2012.09215.x","article-title":"Raynaud-like phenomenon in two patients on nilotinib","volume":"158","author":"Hazenberg","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0600","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.clml.2012.04.005","article-title":"Nilotinib-associated vascular events","volume":"12","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0605","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3747\/co.v18i3.782","article-title":"Digital necrosis induced by erlotinib treatment in metastatic adenocarcinoma of the lung","volume":"18","author":"Ballardini","year":"2011","journal-title":"Curr Oncol"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0610","first-page":"408","article-title":"Association of Raynaud\u2019s syndrome with interferons","volume":"31","author":"Mohokum","year":"2012","journal-title":"A meta-analysis. Int Angiol"},{"issue":"3","key":"10.2515\/therapie\/2013068_bb0615","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/sarh.2002.34606","article-title":"Interferon-induced Raynaud\u2019s syndrome","volume":"32","author":"Schapira","year":"2002","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0620","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000040874","article-title":"Interferon-induced vasospasm in chronic myeloid leukaemia","volume":"100","author":"Zeidman","year":"1998","journal-title":"Acta Haematol"},{"issue":"11","key":"10.2515\/therapie\/2013068_bb0625","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1023\/A:1026586629166","article-title":"Interferon-\u03b1 induced Raynaud\u2019s syndrome","volume":"11","author":"Kruit","year":"2000","journal-title":"Ann Oncol"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0630","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00228-002-0552-4","article-title":"Raynaud\u2019s phenomenon induced by drugs acting on neurotransmission: two cases under reboxetine and one under tegaserod","volume":"58","author":"Bertoli","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.2515\/therapie\/2013068_bb0635","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.23301","article-title":"Association between treatment with central nervous system stimulants and Raynaud\u2019s syndrome in children: A retrospective case\u2013control study of rheumatology patients","volume":"58","author":"Goldman","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.2515\/therapie\/2013068_bb0640","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/cap.2012.0131","article-title":"Dose-dependent Raynaud\u2019s phenomenon developing from use of atomoxetine in a girl","volume":"23","author":"G\u00f6k\u00e7en","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0645","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/ndt\/14.7.1761","article-title":"Peripheral vasculopathy and nephropathy in association with phentermine","volume":"14","author":"Jefferson","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"2, Part 2","key":"10.2515\/therapie\/2013068_bb0650","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lpm.2007.07.006","article-title":"Prise en charge des ulc\u00e8res digitaux de la scl\u00e9rodermie syst\u00e9mique : recommandations d\u2019un groupe pluridisciplinaire d\u2019experts","volume":"37","author":"Franc\u00e8s","year":"2008","journal-title":"Presse Med"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0655","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4997\/JRCPE.2012.106","article-title":"Digital gangrene in a patient with primary Raynaud\u2019s phenomenon","volume":"42","author":"Ravindran","year":"2012","journal-title":"J R Coll Physicians Edinb"},{"issue":"5","key":"10.2515\/therapie\/2013068_bb0660","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s100670170031","article-title":"Cocaine-induced raynaud\u2019s phenomenon and ischaemic finger necrosis","volume":"20","author":"Balbir-Gurman","year":"2001","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.2515\/therapie\/2013068_bb0665","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1368-5031.2005.00566a.x","article-title":"Cyclosporine--a treatment and a rare complication: Raynaud\u2019s phenomenon","volume":"59","author":"Arinsoy","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"9-10","key":"10.2515\/therapie\/2013068_bb0670","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1432-2277.2002.tb00209.x","article-title":"Cyclosporin A-related Raynaud\u2019s phenomenon in a renal transplant recipient","volume":"15","author":"Sharma","year":"2002","journal-title":"Transpl Int"},{"issue":"1","key":"10.2515\/therapie\/2013068_bb0675","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.annder.2008.10.025","article-title":"Intravenous fluorescein and Raynaud\u2019s phenomenon","volume":"136","author":"Schmutz","year":"2009","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"10.2515\/therapie\/2013068_bb0680","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1600-0420.2007.00953.x","article-title":"Fluorescein-induced Raynaud\u2019s phenomenon","volume":"85","author":"Blaise","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"4","key":"10.2515\/therapie\/2013068_bb0685","first-page":"370","article-title":"Raynaud\u2019s phenomenon induced by sulphasalazine in a case of chronic ulcerative colitis","volume":"32","author":"Ahmad","year":"1984","journal-title":"J Assoc Physicians India"},{"issue":"652","key":"10.2515\/therapie\/2013068_bb0690","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/pgmj.56.652.106","article-title":"Raynaud\u2019s phenomenon induced by sulphasalazine","volume":"56","author":"Reid","year":"1980","journal-title":"Postgrad Med J"},{"issue":"10","key":"10.2515\/therapie\/2013068_bb0695","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1R093","article-title":"Paradoxical reaction of Raynaud phenomenon following the repeated administration of iloprost in a patient with diffuse cutaneous systemic sclerosis","volume":"46","author":"Barreira","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.2515\/therapie\/2013068_bb0700","first-page":"2503","article-title":"Severe Raynaud\u2019s phenomenon with yohimbine therapy for erectile dysfunction","volume":"30","author":"Johnson","year":"2003","journal-title":"J Rheumatol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716309672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T18:36:03Z","timestamp":1716834963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716309672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0040595716309672"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2013068","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}